Literature DB >> 23765416

Noncurative gastrectomy for gastric adenocarcinoma should only be performed in highly selected patients.

Benjamin Schmidt1, Nicole Look-Hong, Ugwuji N Maduekwe, Kevin Chang, Theodore S Hong, Eunice L Kwak, Gregory Y Lauwers, David W Rattner, John T Mullen, Sam S Yoon.   

Abstract

BACKGROUND: The benefit of surgical resection in patients with incurable gastric adenocarcinoma is controversial.
METHODS: A total of 289 patients who presented with advanced or metastatic gastric cancer from 1995 to 2010 were retrospectively reviewed.
RESULTS: Ten patients (3.5 %) required emergent surgery at presentation and were excluded from further analyses. Patients who underwent nonemergent surgery at presentation (n = 110, 38.1 %) received either gastric resection (group A, n = 46, 42 %) or surgery without resection (group B, n = 64, 58 %). Procedures in group A included distal gastrectomy (n = 25, 54 %), total gastrectomy (n = 17, 37 %), and proximal/esophagogastrectomy (n = 4, 9 %). Procedures in group B included laparoscopy (n = 17, 27 %), open exploration (n = 25, 39 %), gastrostomy and/or jejunostomy tube (n = 12, 19 %), and gastrojejunostomy (n = 10, 16 %). Group A required a stay in the intensive care unit or additional invasive procedure significantly more often than group B (15 vs. 2 %, p = 0.009). Four patients in group A (8.7 %) and three patients in group B (4.7 %) died within 30 days of surgery (p = 0.45). When the 110 patients who underwent nonemergent surgery (groups A and B) were compared to nonoperatively managed patients (group C, n = 169, 58 %), median overall survival did not significantly differ (8.6 vs. 9.2 vs. 7.7 months; p > 0.05). Three patients in group B (4.7 %) and three in group C (1.8 %) ultimately required an operation for their primary tumor.
CONCLUSIONS: Patients with gastric adenocarcinoma who present with advanced or metastatic disease not amenable to curative resection infrequently require emergent surgery. Noncurative resection is associated with significant perioperative morbidity and mortality as well as limited overall survival, and should therefore be performed judiciously.

Entities:  

Mesh:

Year:  2013        PMID: 23765416     DOI: 10.1245/s10434-013-3024-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Techniques of intragastric laparoscopic surgery.

Authors:  Claudius Conrad; Marius Nedelcu; Satoshi Ogiso; Thomas A Aloia; Jean-Nicolas Vauthey; Brice Gayet
Journal:  Surg Endosc       Date:  2014-08-09       Impact factor: 4.584

Review 2.  Treatment of gastric cancer.

Authors:  Michele Orditura; Gennaro Galizia; Vincenzo Sforza; Valentina Gambardella; Alessio Fabozzi; Maria Maddalena Laterza; Francesca Andreozzi; Jole Ventriglia; Beatrice Savastano; Andrea Mabilia; Eva Lieto; Fortunato Ciardiello; Ferdinando De Vita
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 3.  Palliative care for advanced gastric cancer.

Authors:  Kazuto Harada; Meina Zhao; Namita Shanbhag; Hideo Baba; Jaffer A Ajani
Journal:  Expert Rev Anticancer Ther       Date:  2020-06-23       Impact factor: 4.512

4.  Analysis of surgery for incurable gastric cancer.

Authors:  Honguang Zhao; Wenhu Chen; Yehua Lin; Jiangfeng Qin; Lifang Wang
Journal:  World J Surg Oncol       Date:  2015-12-18       Impact factor: 2.754

5.  The impact and optimal indication of non-curative gastric resection for stage IV advanced gastric cancer diagnosed during surgery: 10 years of experience at a single institute.

Authors:  Naoya Yamada; Atsushi Akai; Yukihiro Nomura; Nobutaka Tanaka
Journal:  World J Surg Oncol       Date:  2016-03-10       Impact factor: 2.754

6.  Primary Tumor Resection and Survival in Patients with Stage IV Gastric Cancer.

Authors:  Fatma Yalçin Müsri; Hasan Mutlu; Mustafa Karaağaç; Melek Karakurt Eryilmaz; Şeyda Gündüz; Mehmet Artaç
Journal:  J Gastric Cancer       Date:  2016-06-24       Impact factor: 3.720

7.  Palliative Gastrectomy Prolongs Survival of Metastatic Gastric Cancer Patients with Normal Preoperative CEA or CA19-9 Values: A Retrospective Cohort Study.

Authors:  Chang-Fang Chiu; Horng-Ren Yang; Mei-Due Yang; Long-Bin Jeng; Tse-Yen Yang; Aaron M Sargeant; Li-Yuan Bai
Journal:  Gastroenterol Res Pract       Date:  2016-11-29       Impact factor: 2.260

Review 8.  Systematic review of partial hepatic resection to treat hepatic metastases in patients with gastric cancer.

Authors:  Di Long; Peng-Cheng Yu; Wei Huang; Yu-Long Luo; Sen Zhang
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

9.  Is noncurative gastrectomy always a beneficial strategy for stage IV gastric cancer?

Authors:  Chang Min Lee; In Keun Choi; Jong-Han Kim; Da Won Park; Jun Suk Kim; Seong-Heum Park
Journal:  Ann Surg Treat Res       Date:  2016-12-30       Impact factor: 1.859

Review 10.  Hepatectomy for liver metastases from gastric cancer: a systematic review.

Authors:  Ying-Yang Liao; Ning-Fu Peng; Di Long; Peng-Cheng Yu; Sen Zhang; Jian-Hong Zhong; Le-Qun Li
Journal:  BMC Surg       Date:  2017-02-13       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.